IQVIA Seeks Eligible Participants for Clinical Research Study for Treatment non-small cell Lung Cancer
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer and impacts close to 85% of diagnosed patients
Coping with lung cancer can be stressful for you and your family. Participating in this study can provide you with useful information which will be helpful in managing your condition.
A clinical research study of an investigational medication used in combination with chemotherapy for the treatment of non-small cell lung cancer (NSCLC) is seeking eligible participants to compare the safety and efficacy BAT1706 and (EU) Avastin®. IQVIA (IMS Health and Quintiles) is actively recruiting for this study.
The purpose of this research study is to see how well the study medication works when it is used together with chemotherapy in participants with advanced non-squamous non-small cell lung cancer (nsNSCLC).
During the 3-week screening period, your study doctor will make sure that this study is right for you.
The duration of participation for each participant is expected to be about 12 months (up to 17 cycles). Participants who are still benefiting of bevacizumab after 12 months of treatment will have the option to continue treatment with BAT1706 in a Long term extension (LTE) study for a maximum of 12 additional months depending on protocol criteria.
This research study was approved by the South African Health Products Regulatory Authority, Pharma-Ethics Committee and the University of Pretoria Ethics Committee.
The closing date for recruitment is 31 March 2019.
Please note, CANSA has no affiliation with, or involvement in, any clinical trials.
If you, or someone you know is interested to participate or would like more information about the study, please contact the study team at:
Phone: 012 354 1054
Phone: 051 405 2652
Cape Town (Northern Suburbs)
Phone: 021 944 3832
Cape Town (Southern Suburbs)
Phone: 021 180 3710